Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exablate BBB Disruption with Microbubble Resonators plus Carboplatin in Recurrent Glioblastoma
2020-003127-41Phase 2Completed
- Sponsor
- Insightec
- Start
- Jun 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carboplatin in glioblastoma (GBM), sponsored by Insightec. Primary endpoints: Safety of Exablate BBB disruption with microbubble resonators plus carboplatin and Feasibility of Exablate BBB disruption procedure. Started Jun 2021; status: completed.
02
Drugs
carboplatin
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2020-003127-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003127-41.